Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/ 2a, Multicenter Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

NCT05417932 is registered in ClinicalTrials.gov with SCG Cell Therapy Pte. Ltd. as lead sponsor.

NCT NCT05417932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05417932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/ 2a, Multicenter Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
Lead sponsor
SCG Cell Therapy Pte. Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 26, 2022
Completion date
October 31, 2025
Enrollment
46 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b virus related hepatocellular carcinoma, hepatocellular carcinoma recurrent